

# Paraskevi V Voulgari

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4881850/publications.pdf>

Version: 2024-02-01

172  
papers

3,543  
citations

159585

30  
h-index

161849

54  
g-index

177  
all docs

177  
docs citations

177  
times ranked

4395  
citing authors

#	ARTICLE	IF	CITATIONS
1	Correspondence on "Cardiovascular effects of biological versus csDMARD therapy in treatment naive, early rheumatoid arthritis"™. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e89-e89.	0.9	1
2	The changing incidence of rheumatoid arthritis over time in north-west Greece: data from a referral centre. <i>Scandinavian Journal of Rheumatology</i> , 2023, 52, 327-334.	1.1	7
3	Opportunistic screening for hypertension: what does it say about the true epidemiology?. <i>Journal of Human Hypertension</i> , 2022, 36, 364-369.	2.2	3
4	Neuroinflammatory events after anti-TNF± therapy. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e73-e73.	0.9	6
5	Fibroblastic rheumatism: an uncommon arthritis. A case-based review. <i>Rheumatology International</i> , 2022, 42, 1097-1103.	3.0	1
6	TNF-induced Lupus. A Case-Based Review. <i>Current Rheumatology Reviews</i> , 2022, 18, 72-82.	0.8	5
7	Seronegative Erosive Arthritis Following SARS-CoV-2 Infection. <i>Rheumatology and Therapy</i> , 2022, 9, 295-301.	2.3	8
8	Colchicine Against SARS-CoV-2 Infection: What is the Evidence?. <i>Rheumatology and Therapy</i> , 2022, 9, 379-389.	2.3	12
9	Long COVID from rheumatology perspective: a simple mimicker or promoter of autoimmunity?. <i>Clinical Rheumatology</i> , 2022, 41, 957-958.	2.2	5
10	A Patient with Symmetrical Polyarthritis. The Value of Conventional Radiography for a Correct Diagnosis. <i>Rheumatology and Therapy</i> , 2022, 9, 771-779.	2.3	4
11	Thyroid dysfunction in Greece: Results from the national health examination survey EMENO. <i>PLoS ONE</i> , 2022, 17, e0264388.	2.5	3
12	Adiponectin, leptin and resistin levels in first-episode, drug-naïve patients with psychosis before and after short-term antipsychotic treatment. <i>Journal of Psychosomatic Research</i> , 2022, 157, 110789.	2.6	3
13	Orbital myositis in systemic lupus erythematosus: a case-based review. <i>Rheumatology International</i> , 2022, 42, 1453-1460.	3.0	2
14	TNF± inhibitor biosimilars associated with alopecia areata. Case-based review. <i>Rheumatology International</i> , 2022, 42, 1113-1117.	3.0	3
15	Hyperlipidemia and rheumatoid arthritis. , 2022, , 969-997.		0
16	Treatment strategies of Covid-19. A rheumatology perspective.. <i>European Journal of Internal Medicine</i> , 2022, , .	2.2	3
17	Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 485-493.	3.0	9
18	The effects of biologic agents on cardiovascular risk factors and atherosclerosis in rheumatoid arthritis patients: a prospective observational study. <i>Heart and Vessels</i> , 2022, 37, 2128-2136.	1.2	2

#	ARTICLE	IF	CITATIONS
19	Preclinical discovery and development of adalimumab for the treatment of rheumatoid arthritis. Expert Opinion on Drug Discovery, 2021, 16, 227-234.	5.0	10
20	Calcified constrictive pericarditis resulting in tamponade in a patient with systemic lupus erythematosus. Rheumatology International, 2021, 41, 651-670.	3.0	4
21	Occupational mimics of rheumatoid arthritis: hair dye-induced arthritis. Rheumatology International, 2021, 41, 795-797.	3.0	3
22	Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis. Rheumatology, 2021, 60, 2223-2230.	1.9	8
23	Biologic Therapies and Autoimmune Phenomena. Mediterranean Journal of Rheumatology, 2021, 32, 96.	0.8	10
24	Prevalence of diabetes and pre-diabetes in Greece. Results of the First National Survey of Morbidity and Risk Factors (EMENO) study. Diabetes Research and Clinical Practice, 2021, 172, 108646.	2.8	6
25	Insulin resistance in patients with rheumatoid arthritis. Rheumatology International, 2021, 41, 1185-1186.	3.0	2
26	Pleural effusion in psoriatic arthritis patients: a case series and review of the literature. Clinical Rheumatology, 2021, 40, 4741-4748.	2.2	2
27	Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience. Rheumatology International, 2021, 41, 903-909.	3.0	9
28	Current Therapeutic Options for the Treatment of Juvenile Idiopathic Arthritis. Current Rheumatology Reviews, 2021, 17, 41-57.	0.8	2
29	Methotrexate and interstitial lung disease. Is there a real causative factor?. Rheumatology International, 2021, 41, 2045-2046.	3.0	1
30	Cutaneous Autoimmune Phenomena of the Anti-TNF $\alpha$ Biosimilars. Casebased Review. Current Rheumatology Reviews, 2021, 17, 267-270.	0.8	6
31	COVID-19 in patients with gout on colchicine. Rheumatology International, 2021, 41, 1503-1507.	3.0	10
32	Role of Hepcidin in Anemia of Chronic Disease in Rheumatoid Arthritis. Journal of Laboratory Physicians, 2021, 13, 317-322.	1.1	4
33	A biomarker for lymphoma development in Sjogren's syndrome: Salivary gland focus score. Journal of Autoimmunity, 2021, 121, 102648.	6.5	24
34	Single photon emission computed tomography myocardial perfusion imaging in patients with moderate to severe psoriasis. Nuclear Medicine Review, 2021, 24, 46-50.	0.5	1
35	Prevalence of tobacco smoking and association with other unhealthy lifestyle risk factors in the general population of Greece: Results from the EMENO study. Tobacco Prevention and Cessation, 2021, 7, 1-13.	0.4	6
36	A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases. Journal of Autoimmunity, 2021, 125, 102743.	6.5	45

#	ARTICLE	IF	CITATIONS
37	A not-to-miss Cause of Severe Cervical Spine Pain in a Patient with Rheumatoid Arthritis: A Case-Based Review. <i>Mediterranean Journal of Rheumatology</i> , 2021, 32, 256.	0.8	1
38	Prevalence, awareness, treatment and control of hypertension in Greece: EMENO national epidemiological study. <i>Journal of Hypertension</i> , 2021, 39, 1034-1039.	0.5	8
39	Combined seronegativity in Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
40	Combined seronegativity in Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 80-84.	0.8	8
41	Successful treatment with rituximab of IgG4-related disease coexisting with adult-onset asthma and periocular xanthogranuloma. <i>Rheumatology International</i> , 2020, 40, 671-677.	3.0	10
42	Reply to the Editor. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, e7.	3.4	0
43	<i>Aeromonas hydrophila</i> Survives the Treatment of Posttraumatic Cellulitis in the Shelter of an Obscured Fish-Bone Fragment. <i>Case Reports in Dermatological Medicine</i> , 2020, 2020, 1-3.	0.3	0
44	High prevalence of cardiovascular risk factors in adults living in Greece: the EMENO National Health Examination Survey. <i>BMC Public Health</i> , 2020, 20, 1665.	2.9	21
45	Sjögren's Syndrome: The Clinical Spectrum of Male Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 2620.	2.4	26
46	Primary Sjögren's Syndrome of Early and Late Onset: Distinct Clinical Phenotypes and Lymphoma Development. <i>Frontiers in Immunology</i> , 2020, 11, 594096.	4.8	45
47	Recent advances in the opioid mu receptor based pharmacotherapy for rheumatoid arthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2153-2160.	1.8	7
48	Radiological Findings of the Cervical Spine in Rheumatoid Arthritis: What a Rheumatologist Should Know. <i>Current Rheumatology Reports</i> , 2020, 22, 19.	4.7	11
49	The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk. <i>Rheumatology International</i> , 2020, 40, 1181-1191.	3.0	38
50	Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort. <i>Arthritis Research and Therapy</i> , 2020, 22, 56.	3.5	12
51	Therapeutic Options and Cost-Effectiveness for Rheumatoid Arthritis Treatment. <i>Current Rheumatology Reports</i> , 2020, 22, 44.	4.7	15
52	Treatment strategies are more important than drugs in the management of rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2020, 39, 1363-1368.	2.2	47
53	Cardiovascular risk factors in HIV infected individuals: Comparison with general adult control population in Greece. <i>PLoS ONE</i> , 2020, 15, e0230730.	2.5	24
54	Adalimumab-induced myasthenia gravis: case-based review. <i>Rheumatology International</i> , 2020, 40, 1891-1894.	3.0	8

#	ARTICLE	IF	CITATIONS
55	Cardiovascular Disease in Spondyloarthritis. <i>Current Vascular Pharmacology</i> , 2020, 18, 473-487.	1.7	8
56	Anti-Rheumatic Drugs for the Fight Against the Novel Coronavirus Infection (SARSCoV-2): What is the Evidence?. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 259.	0.8	14
57	FRIO493â€¦THE INTERLEUKIN-1B INHIBITOR CANAKINUMAB FOR REFRACTORY STILLâ€™S DISEASE: LONG-TERM EXPERIENCE IN 50 CONSECUTIVE PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 845.1-845.	0.9	0
58	Clinical, Serological and Immunological Characteristics in Greek Patients with Psoriatic Arthritis: The Role of IL-17, IL-23, and Sclerostin. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 235.	0.8	1
59	Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 597-602.	3.4	33
60	Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?. <i>Journal of Clinical Medicine</i> , 2019, 8, 1237.	2.4	19
61	&lt;p&gt;Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis&lt;/p&gt;. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 1073-1079.	2.0	14
62	Comment on: Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry. <i>Rheumatology</i> , 2019, 58, 1883-1884.	1.9	4
63	Conventional radiography of the hands and wrists in rheumatoid arthritis. What a rheumatologist should know and how to interpret the radiological findings. <i>Rheumatology International</i> , 2019, 39, 1331-1341.	3.0	17
64	Eight-year survival study of first-line tumour necrosis factor Î± inhibitors in rheumatoid arthritis: real-world data from a university centre registry. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz007.	0.7	21
65	Golimumab for Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2019, 8, 387.	2.4	34
66	Unmet needs in the treatment of ankylosing spondylitis: a long-term observational study from a single university center. <i>Rheumatology International</i> , 2019, 39, 663-668.	3.0	1
67	The impact of temporal artery biopsy for the diagnosis of giant cell arteritis in clinical practice in a tertiary university hospital. <i>PLoS ONE</i> , 2019, 14, e0210845.	2.5	8
68	THU0671â€¦PULMONARY INVOLVEMENT IN RHEUMATOID ARTHRITIS: PATTERNS AND EPIDEMIOLOGICAL CHARACTERISTICS FROM A MONOCENTRIC COHORT STUDY. , 2019, , .		0
69	AB1272â€¦TREATMENT OF RHEUMATOID ARTHRITIS WITH EXTENSION OF THE ANTI-TNF INTERDOSE INTERVALS. A MONOCENTRIC OFF-LABEL STUDY. , 2019, , .		0
70	AB0678â€¦ANTIPROLIFERATIVE AND VASOACTIVE TREATMENT MODALITIES IN 457 CONSECUTIVE PATIENTS WITH SYSTEMIC SCLEROSIS FROM ACADEMIC CENTERS IN GREECE. , 2019, , .		0
71	SAT0247â€¦FEMALE SEX AND AGE AT DIAGNOSIS ARE ASSOCIATED WITH A DECREASED POSSIBILITY OF DRUG DISCONTINUATION IN GIANT CELL ARTERITIS: DATA FROM A MULTICENTER PROSPECTIVE COHORT OF 177 PATIENTS. , 2019, , .		0
72	Granuloma annulare development in a patient with rheumatoid arthritis treated with tocilizumab: case-based review. <i>Rheumatology International</i> , 2019, 39, 353-357.	3.0	12

#	ARTICLE	IF	CITATIONS
73	National Survey of Morbidity and Risk Factors (EMENO): Protocol for a Health Examination Survey Representative of the Adult Greek Population. <i>JMIR Research Protocols</i> , 2019, 8, e10997.	1.0	14
74	Fasting mimicking diets: A literature review of their impact on inflammatory arthritis. <i>Mediterranean Journal of Rheumatology</i> , 2019, 30, 201.	0.8	14
75	Epidemiological characteristics of psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 324-332.	0.8	1
76	Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence. <i>Journal of Rheumatology</i> , 2018, 45, 785-794.	2.0	43
77	ABP 501 for the treatment of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 317-322.	3.1	14
78	Liver perivascular epithelioid cell tumor in a patient with systemic lupus erythematosus. <i>International Journal of Surgery Case Reports</i> , 2018, 53, 193-195.	0.6	5
79	An Extensive Study of the Functional Polymorphisms of Kinin-Kallikrein System in Rheumatoid Arthritis Susceptibility. <i>Archives of Rheumatology</i> , 2018, 33, 33-38.	0.9	3
80	Image Gallery: Capillaroscopy for noninvasive scabies diagnosis. <i>British Journal of Dermatology</i> , 2018, 179, e133-e133.	1.5	0
81	Sjögren Syndrome Associated with Inflammatory Muscle Diseases. <i>Mediterranean Journal of Rheumatology</i> , 2018, 29, 92-96.	0.8	8
82	AB0720...Systemic sclerosis and cancer development. a single-centre experience. , 2018, , .		0
83	FR10101...Unmet needs in the treatment of rheumatoid arthritis. an observational study and a real-life experience from a single university centre. , 2018, , .		0
84	Five-year prospective multi-center cohort study of patients with giant cell arteritis in Greece. <i>Mediterranean Journal of Rheumatology</i> , 2018, 29, 103-105.	0.8	2
85	Uncommon presentation of granulomatosis with polyangiitis in association with subclinical coeliac disease. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 111, 160.	0.8	0
86	High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 254-262.	0.8	17
87	Sirukumab: a promising therapy for rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 755-763.	3.1	16
88	A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor. <i>Rheumatology and Therapy</i> , 2017, 4, 509-513.	2.3	4
89	AB0476...Inner ear involvement in systemic rheumatic diseases. , 2017, , .		0
90	Changes in the cytokine profile in first-episode, drug-naïve patients with psychosis after short-term antipsychotic treatment. <i>Psychiatry Research</i> , 2017, 256, 378-383.	3.3	11

#	ARTICLE	IF	CITATIONS
91	Transfusion-related acute lung injury in a patient with systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 353.	0.8	1
92	Joint complaints correlate with increased serum IgE levels in patients hospitalized for moderate-to-severe psoriasis: A single center retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1014-1015.e4.	1.2	2
93	SAT0382â€¦Therapeutic Response in Psoriatic Arthritis Patients Receiving Biological or Conventional Disease Modifying Antirheumatic Drugs. A 5-Year Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 806.2-806.	0.9	0
94	Evidence of <i>ERBB3</i> gene association with rheumatoid arthritis predisposition. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 146-149.	1.9	2
95	THU0130â€¦Mental Illness, Suicidality Risk and Associated Illness Perceptions in People with Chronic Inflammatory Rheumatic Diseases Seeking Urgent Care in the Emergency Department. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 241.1-241.	0.9	0
96	SAT0234â€¦Counting Costs Under Severe Financial Constraints: A Cost of Illness Analysis of Spondyloarthropathies in Greece. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 743.2-743.	0.9	0
97	Cytokine profile in drug-naïve, first episode patients with psychosis. <i>Journal of Psychosomatic Research</i> , 2015, 79, 324-327.	2.6	18
98	Counting Costs under Severe Financial Constraints: A Cost-of-Illness Analysis of Spondyloarthropathies in a Tertiary Hospital in Greece. <i>Journal of Rheumatology</i> , 2015, 42, 963-967.	2.0	5
99	Impaired Antiatherogenic Functions of High-density Lipoprotein in Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2015, 42, 1652-1660.	2.0	22
100	Golimumab, the newest TNF-Î± blocker, comes of age. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 570-7.	0.8	13
101	Tuberculous pyomyositis in a rheumatoid arthritis patient treated with anakinra. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 734-6.	0.8	9
102	AB0123â€¦Antibodies to Porphyromonas Gingivalis in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 844.3-844.	0.9	0
103	In transit Recurrence of Merkel Cell Carcinoma Associated with Polyarthritis Effectively Treated with Immunocryosurgery. <i>Acta Dermato-Venereologica</i> , 2014, 94, 739-740.	1.3	8
104	Effect of Hydroxychloroquine on the Lipid Profile of Patients with Sjögren Syndrome. <i>Journal of Rheumatology</i> , 2014, 41, 902-908.	2.0	18
105	Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study. <i>Arthritis Research and Therapy</i> , 2014, 16, R125.	3.5	87
106	Reply to the comment "Effect of Infliximab on Male Fertility" by Younis et al.. <i>Joint Bone Spine</i> , 2014, 81, 103.	1.6	1
107	Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 447-457.	3.4	80
108	Demyelination and other neurological adverse events after anti-TNF therapy. <i>Autoimmunity Reviews</i> , 2014, 13, 54-58.	5.8	147

#	ARTICLE	IF	CITATIONS
109	Cardiovascular risk profile in patients with spondyloarthritis. <i>Joint Bone Spine</i> , 2014, 81, 57-63.	1.6	63
110	FR10415â€¦Patients' Illness Perceptions Are Associated with Physical Health-Related Quality of Life Independent of Psychological Distress and Disease Severity in Primary Sjogren's Syndrome, Systemic Lupus Erythematosus and Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 537.3-537.	0.9	0
111	AB0743â€¦Prevalence of the Metabolic Syndrome According to Various Definitions in Patients with Psoriatic Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1049.2-1049.	0.9	0
112	AB0683â€¦Prevalence of the Metabolic Syndrome According to Various Definitions in Patients with Ankylosing Spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1031.1-1031.	0.9	0
113	Certolizumab for rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 415-23.	0.8	11
114	Altered sequence of the <i>ETS1</i> transcription factor may predispose to rheumatoid arthritis susceptibility. <i>Scandinavian Journal of Rheumatology</i> , 2013, 42, 11-14.	1.1	17
115	Avascular necrosis in a patient with systemic lupus erythematosus. <i>Joint Bone Spine</i> , 2013, 80, 665.	1.6	2
116	A7.19â€¦Positive Association of TAGAP Rs212389 Polymorphism with Rheumatoid Arthritis Susceptibility. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A54.3-A55.	0.9	1
117	Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study. <i>Scandinavian Journal of Rheumatology</i> , 2013, 42, 169-175.	1.1	27
118	A7.13â€¦IRAK1 Rs3027898 Polymorphism: A Variant Implicated in the Pathogenesis of more than one Inflammatory Disease. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A52.2-A52.	0.9	0
119	A7.12â€¦Identification of the Semaphorin Receptor Plexin-A2 as a Candidate Gene for Susceptibility to Ankylosing Spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A52.1-A52.	0.9	0
120	AB0012â€¦Positive association of tagap rs212389 polymorphism with rheumatoid arthritis susceptibility. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A789.3-A789.	0.9	0
121	AB0924â€¦Psychological distress symptoms and illness perceptions associated with health-related quality of life in psoriatic arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 691.12-691.	0.9	0
122	THU0432â€¦Bone erosions in rheumatoid arthritis: Ultrasound findings in the early stage of the disease. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 301.2-301.	0.9	4
123	A7.22â€¦The ETS1 Transcription Factor May Predispose to Rheumatoid Arthritis Susceptibility. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A55.3-A56.	0.9	0
124	AB0013â€¦First report of erbb3 gene association with rheumatoid arthritis predisposition. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A789.4-A789.	0.9	0
125	FR10179â€¦Infliximab infusion reactions in patients with rheumatoid arthritis and spondylarthropathies. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A432.2-A432.	0.9	0
126	Effect of very early treatment in rheumatoid arthritis on bone oedema and synovitis, using magnetic resonance imaging. <i>Scandinavian Journal of Rheumatology</i> , 2012, 41, 339-344.	1.1	10



#	ARTICLE	IF	CITATIONS
127	Rheumatoid arthritis in patients with hemoglobinopathies. <i>Rheumatology International</i> , 2012, 32, 2889-2892.	3.0	13
128	Adalimumab in the treatment of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1679-1686.	3.1	14
129	Prognostic Factors of Radiological Damage in Rheumatoid Arthritis: A 10-year Retrospective Study. <i>Journal of Rheumatology</i> , 2011, 38, 44-52.	2.0	39
130	Sustained Clinical Response in Psoriatic Arthritis Patients Treated with Anti-TNF Agents: A 5-year Open-Label Observational Cohort Study. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 40, 398-406.	3.4	44
131	Coping with health-stressors and defence styles associated with health-related quality of life in patients with systemic lupus erythematosus. <i>Lupus</i> , 2011, 20, 893-903.	1.6	33
132	Rheumatological manifestations in inflammatory bowel disease. <i>Annals of Gastroenterology</i> , 2011, 24, 173-180.	0.6	30
133	Maintained clinical response of infliximab treatment in ankylosing spondylitis: A 6-year long-term study. <i>Joint Bone Spine</i> , 2010, 77, 325-329.	1.6	24
134	Transfusion-related Acute Lung Injury During Intravenous Immunoglobulin Treatment. <i>Journal of Rheumatology</i> , 2010, 37, 190-191.	2.0	14
135	Golimumab: a new anti-TNF- $\alpha$ agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 721-733.	3.0	11
136	Long-term use of adalimumab in the treatment of rheumatic diseases. <i>Open Access Rheumatology: Research and Reviews</i> , 2009, 1, 51.	1.6	3
137	The role of psychological distress and personality variables in the disablement process in rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2009, 38, 419-430.	1.1	38
138	Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. <i>Scandinavian Journal of Rheumatology</i> , 2009, 38, 328-331.	1.1	85
139	Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab. <i>Clinical and Experimental Rheumatology</i> , 2009, 27, 996-8.	0.8	23
140	Sustained Clinical Response and High Infliximab Survival in Psoriatic Arthritis Patients: A 3-year Long-Term Study. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 37, 293-298.	3.4	20
141	Early Treatment Reduces the Cardiovascular Risk Factors in Newly Diagnosed Rheumatoid Arthritis Patients. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 38, 13-19.	3.4	97
142	Emerging drugs for rheumatoid arthritis. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 175-196.	2.4	20
143	Granuloma annulare induced by anti-tumour necrosis factor therapy. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 567-570.	0.9	97
144	Catastrophic rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 2062-3.	2.0	0

#	ARTICLE	IF	CITATIONS
145	Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis. <i>Rheumatology International</i> , 2007, 27, 935-939.	3.0	18
146	Adalimumab for rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 1349-1360.	3.1	23
147	Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 257-260.	0.9	94
148	Psychological distress and personality traits in early rheumatoid arthritis: a preliminary survey. <i>Rheumatology International</i> , 2006, 26, 828-836.	3.0	30
149	Esophageal Involvement in Scleroderma: Gastroesophageal Reflux, the Common Problem. <i>Seminars in Arthritis and Rheumatism</i> , 2006, 36, 173-181.	3.4	93
150	Incidence and Prevalence of Rheumatoid Arthritis, Based on the 1987 American College of Rheumatology Criteria: A Systematic Review. <i>Seminars in Arthritis and Rheumatism</i> , 2006, 36, 182-188.	3.4	621
151	Persistent Clinical Response of Infliximab Therapy in Patients with Refractory Rheumatoid Arthritis, over a 3-Year Period. <i>Current Clinical Pharmacology</i> , 2006, 1, 103-108.	0.6	3
152	Subcutaneous lesions in dermatomyositis. <i>Rheumatology</i> , 2006, 45, 165-165.	1.9	2
153	Magnetic resonance imaging quantification of hand synovitis in patients with rheumatoid arthritis treated with adalimumab. <i>Journal of Rheumatology</i> , 2006, 33, 219-23.	2.0	32
154	Laryngeal involvement in rheumatoid arthritis. <i>Rheumatology International</i> , 2005, 25, 321-325.	3.0	56
155	A single pulmonary rheumatoid nodule masquerading as malignancy. <i>Clinical Rheumatology</i> , 2005, 24, 556-559.	2.2	7
156	Infliximab therapy in established rheumatoid arthritis: An observational study. <i>American Journal of Medicine</i> , 2005, 118, 515-520.	1.5	53
157	Radiological cervical spine involvement in patients with rheumatoid arthritis: a cross sectional study. <i>Journal of Rheumatology</i> , 2005, 32, 801-6.	2.0	45
158	Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients?. <i>Clinical and Experimental Rheumatology</i> , 2005, 23, 861-6.	0.8	81
159	Epidemiology of ankylosing spondylitis in Northwest Greece, 1983-2002. <i>British Journal of Rheumatology</i> , 2004, 43, 615-618.	2.3	78
160	Antierythropoietin antibodies in thalassemia patients. <i>Annals of Hematology</i> , 2004, 83, 22-27.	1.8	6
161	Sinus histiocytosis with massive lymphadenopathy (Rosai's "Dorfman disease) in a patient with primary Sjogren's syndrome. <i>Scandinavian Journal of Rheumatology</i> , 2004, 33, 119-122.	1.1	8
162	Early rheumatoid arthritis: does gender influence disease expression?. <i>Clinical and Experimental Rheumatology</i> , 2004, 22, 165-70.	0.8	4

#	ARTICLE	IF	CITATIONS
163	Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 1218-1220.	0.9	67
164	Gender and age differences in systemic lupus erythematosus. A study of 489 Greek patients with a review of the literature. <i>Lupus</i> , 2002, 11, 722-729.	1.6	87
165	Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study. <i>Journal of Rheumatology</i> , 2002, 29, 261-6.	2.0	32
166	Gingival hyperplasia associated with cyclosporin A. <i>Journal of Rheumatology</i> , 2002, 29, 2466.	2.0	5
167	FRIO245...Clinical course and outcome in mixed connective tissue disease. , 2001, , .		0
168	Rheumatoid resorptive arthropathy. <i>Clinical and Experimental Rheumatology</i> , 1999, 17, 474-6.	0.8	0
169	Cyclosporine A in the treatment of early rheumatoid arthritis. A prospective, randomized 24-month study. <i>Clinical and Experimental Rheumatology</i> , 1998, 16, 695-701.	0.8	17
170	D-penicillamine in early rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 1997, 15, 580-1.	0.8	3
171	Epidemiology of adult rheumatoid arthritis in northwest Greece 1987-1995. <i>Journal of Rheumatology</i> , 1997, 24, 2129-33.	2.0	70
172	A Response to: Letter to the Editor Regarding the Article: "Colchicine Against SARS-CoV-2 Infection: What is the Evidence?" <i>Rheumatology and Therapy</i> , 0, , .	2.3	0